Seeking Alpha
View as an RSS Feed

Wall Street Advisors  

View Wall Street Advisors' Articles BY TICKER:
  • Opko Spots Another Overlooked Opportunity In MabVax Therapeutics
    Wed, Apr. 8 MBVX 1 Comment

    Summary

    • Opko Health has a strong track record of identifying undervalued companies in which to invest.
    • Opko most recently announced a strategic investment in MabVax Therapeutics which appears to present another such investment opportunity.
    • MabVax has a pipeline consisting of two Phase II cancer vaccines, a novel antibody discovery platform, an existing relationship with Juno Therapeutics, and an enticing value proposition.
  • The Golden Long: Frost's Pershing Gold Poised For A Significant Upside Move
    Wed, Feb. 11 PGLC 36 Comments

    Summary

    • Gold has been strengthening and is on an upward trend in 2015; this becomes even more apparent when gold is priced in foreign currencies.
    • Dr. Phillip Frost's portfolio has been on a tear so far in 2015, but a gold company in which Frost is a significant investor has gone relatively unnoticed still.
    • Pershing Gold has these macro tailwinds at its back along with recent game changing news fundamentally for the company. Its stock price seems poised for significant near-term appreciation.
  • Broadvision Trades Below Cash And Is Significantly Undervalued On Other Assets
       • Jun. 18, 2014 BVSN 5 Comments

    Summary

    • Broadvision is currently undervalued based on its cash alone, as the company has a $44.3 million market cap and $46 million in cash with no debt.
    • The company’s additional assets could total over $100 million, bringing Broadvision’s fair valuation closer to $150 million, over 3 times today’s valuation.
    • Broadvision’s Clearvale technology may be gaining traction as it has been validated by Nissan, Softbank, and numerous other international technology companies. This is the big upside opportunity.
  • Ruthigen IPO Set To Soar; Tetraphase To Find Lower Floor
       • Mar. 25, 2014 RTGN, TTPH 13 Comments

    Summary

    • Ruthigen's IPO provides strong investment opportunity based on relative valuations and addressing unmet market need with potential multi-billion dollar market.
    • Tetraphase Pharmaceuticals in turn presents a short opportunity as a potentially inferior comp a year ahead of Ruthigen with >10x the market cap.
    • Long RTGN and short TTPH is set up to be an ideal pair trade with upside on both ends and decreased market exposure.
  • The Golden Short: Midway Gold Should Be Half Its Current Price
       • Feb. 20, 2014 MDW 47 Comments
  • Icahn Versus Frost
       • Nov. 14, 2013 KDUS 9 Comments
  • Is ExamWorks A Scam?
       • Aug. 8, 2013 EXAM 13 Comments
  • Ignite Your Portfolio With This Radioactive Pair Trade: Short Uranium Resources And Long Energy Fuels
       • Jul. 31, 2013 URRE, UUUU 37 Comments
  • Revisiting Oculus: Earnings Do Little To Ease The Pain
       • Jun. 18, 2013 OCLS 2 Comments
  • Document Security Systems: Near-Term Upside Of 150%
    Editors' Pick • Jun. 4, 2013 DSS 25 Comments
  • Short On Oculus: Wound Care Company Has Left Dirty Scars
       • May. 7, 2013 OCLS 39 Comments